-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Shanghai, China and Gaithersburg, USA, November 1, 2021/PRNewswire/ - Tianjing Bio ("Company") (NASDAQ: IMAB) is a company that is moving from the clinical stage to commercialization Biopharmaceutical companies are committed to target biological research of innovative biological drugs, antibody technology, clinical development and product commercialization in China and the United States, and provide new and effective treatment methods for the urgently needed cancer treatment fields around the world
.
The company today announced two important senior management appointments to further strengthen the senior management team and accelerate the process of becoming a global biopharmaceutical company
With immediate effect, Mr.
Long Jiang (John Long) will serve as the chief financial officer of Tianjing Biotech and will join the company's board of directors, reporting directly to the company's founder and chairman Dr.
Zang Jingwu
.
Mr.
Mr.
Long Jiang will be fully responsible for the company's capital market business (including dual listing), investor relations and corporate financial management
.
As Tianjing Bio is rapidly changing from a clinical-stage biotechnology company to a comprehensive global biopharmaceutical company covering the entire industry chain, the joining of Mr.
At the same time, with immediate effect, Mr.
Zhu Jielun will be transferred to the company's chief strategy officer
.
Mr.
Dr.
Zang Jingwu, founder and chairman of Tianjing Biotech, said: "John is an excellent financial expert and corporate manager with extremely rich industry management experience, as well as medical and health and cross-industry experience
.
He has outstanding professional capabilities.
Mr.
Long Jiang, Chief Financial Officer of Tianjing Biotech, said: "Tianjing Bio has a forward-looking management team and encouraging development vision.
It is a leader among the emerging Chinese biopharmaceutical companies
.
Join Tianjing at this key development node.
Mr.
Zhu Jielun, Chief Strategy Officer of Tianjing Biological, said: "I am very happy that John can become the company's chief financial officer.
His ability and experience are indispensable and valuable assets in the new development stage of Tianjing Biological
.
Welcome John to join me.
About Tianjing Biological
Tianjing Bio (Nasdaq: IMAB) is an innovative international biotechnology company focusing on the R&D, production and commercialization of differentiated and innovative biological drugs in the field of tumor immunity
.
The company’s mission is to "continuously develop innovative biological drugs and truly change the lives of patients".
Forward-looking statement
Certain information disclosed in this press release contains "forward-looking statements
.
" Forward-looking statements contain expressions such as "expected" and "anticipated"
.
Forward-looking statements are made based on the current expectations and assumptions of Tianjing Biological
.
Forward-looking statements involve future events, so there are uncertainties, risks and are affected by changes in circumstances.
These uncertainties, risks and changes in circumstances may be materially different from those expected in the forward-looking statements
.
Forward-looking statements are not statements of historical facts, nor guarantees or confirmations of future performance
.
The documents filed with the US Securities and Exchange Commission set out important factors that may cause actual results to differ materially from the forward-looking statements
.
Unless otherwise required by law, Tianjing Biotech has no obligation to publicly update or revise any forward-looking statements due to new information, future events or other reasons
.
